Cutaneous Melanoma

Melanoma is a common cancer in the US. Treatment for stage IA-IIA melanoma is surgical resection. Anti–PD-1 immunotherapy after surgical excision improves recurrence-free survival in stages IIB-C melanoma. For stage III melanoma, anti–PD-1 immunotherapy or BRAF + MEK inhibitor therapy decreases risk of melanoma recurrence. First-line therapy for metastatic melanoma is dual checkpoint blockade with ipilimumab and nivolumab.

Corresponding Author: John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, 5117 Centre Ave, Ste 1.32, Pittsburgh, PA 15213 (kirkwoodjm@upmc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.